Related Experiment Video
Updated: Jun 17, 2026

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Use of Clinical Pharmacology in Slowing the Myopia Epidemic
1PharmaLogic Development, Inc., San Rafael, California, USA.
Abstract:
Myopia (nearsightedness) is in epidemic proportions in the world today. The eyecare community has long been desirous of pharmacological treatments to slow myopic progression. Most recently, two proprietary formulations of low-dose atropine were approved. In this article, the author summarizes the challenge to develop therapies for a chronic, preventative, and pediatric treatment, and how clinical pharmacologists' knowledge of pharmaceutics, pharmacokinetics, and therapeutics can optimize the development of therapies to slow myopic progression.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacogenomics: Identification of New Drug Targets
